Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial

Joel E. Gallant, Schlomo Staszewski, Anton L. Pozniak, Edwin DeJesus, Jamal M A H Suleiman, Michael D. Miller, Dion F. Coakley, Biao Lu, John J. Toole, Andrew K. Cheng

Research output: Contribution to journalArticle

Abstract

Context: Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. Objective: To evaluate the efficacy and safety of tenofovir DF compared with stavudine in antiretroviral-naive patients. Design, Setting, and Participants: A prospective, randomized, double-blind study conducted at 81 centers in the United States, South America, and Europe from June 9, 2000, to January 30, 2004. A total of 753 patients infected with HIV who were antiretroviral naive were screened and 602 patients entered the study. Intervention Patients were randomized to receive either tenofovir DF (n=299) or stavudine (n=303), with placebo, in combination with lamivudine and efavirenz. Main Outcome Measure: Proportion of patients with HIV RNA levels of less than 400 copies/mL at week 48. Results: In the primary intent-to-treat analysis in which patients with missing data or who added or switched antiretroviral medications before week 48 were considered as failures, the proportion of patients with HIV RNA of less than 400 copies/mL at week 48 was 239 (80%) of 299 in patients receiving tenofovir DF and 253 (84%) of 301 in patients receiving stavudine (95% confidence interval, -10.4% to 1.5%), exceeding the predefined -10% limit for equivalence. However, equivalence was demonstrated in the secondary analyses (HIV RNA

Original languageEnglish (US)
Pages (from-to)191-201
Number of pages11
JournalJournal of the American Medical Association
Volume292
Issue number2
DOIs
StatePublished - Jul 14 2004

Fingerprint

Tenofovir
Stavudine
Safety
HIV
Therapeutics
efavirenz
RNA
Reverse Transcriptase Inhibitors
Lamivudine
South America

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gallant, J. E., Staszewski, S., Pozniak, A. L., DeJesus, E., Suleiman, J. M. A. H., Miller, M. D., ... Cheng, A. K. (2004). Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. Journal of the American Medical Association, 292(2), 191-201. https://doi.org/10.1001/jama.292.2.191

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients : A 3-year randomized trial. / Gallant, Joel E.; Staszewski, Schlomo; Pozniak, Anton L.; DeJesus, Edwin; Suleiman, Jamal M A H; Miller, Michael D.; Coakley, Dion F.; Lu, Biao; Toole, John J.; Cheng, Andrew K.

In: Journal of the American Medical Association, Vol. 292, No. 2, 14.07.2004, p. 191-201.

Research output: Contribution to journalArticle

Gallant, JE, Staszewski, S, Pozniak, AL, DeJesus, E, Suleiman, JMAH, Miller, MD, Coakley, DF, Lu, B, Toole, JJ & Cheng, AK 2004, 'Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial', Journal of the American Medical Association, vol. 292, no. 2, pp. 191-201. https://doi.org/10.1001/jama.292.2.191
Gallant, Joel E. ; Staszewski, Schlomo ; Pozniak, Anton L. ; DeJesus, Edwin ; Suleiman, Jamal M A H ; Miller, Michael D. ; Coakley, Dion F. ; Lu, Biao ; Toole, John J. ; Cheng, Andrew K. / Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients : A 3-year randomized trial. In: Journal of the American Medical Association. 2004 ; Vol. 292, No. 2. pp. 191-201.
@article{ba7699a76bf8436ab94bf87214c56d5a,
title = "Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial",
abstract = "Context: Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. Objective: To evaluate the efficacy and safety of tenofovir DF compared with stavudine in antiretroviral-naive patients. Design, Setting, and Participants: A prospective, randomized, double-blind study conducted at 81 centers in the United States, South America, and Europe from June 9, 2000, to January 30, 2004. A total of 753 patients infected with HIV who were antiretroviral naive were screened and 602 patients entered the study. Intervention Patients were randomized to receive either tenofovir DF (n=299) or stavudine (n=303), with placebo, in combination with lamivudine and efavirenz. Main Outcome Measure: Proportion of patients with HIV RNA levels of less than 400 copies/mL at week 48. Results: In the primary intent-to-treat analysis in which patients with missing data or who added or switched antiretroviral medications before week 48 were considered as failures, the proportion of patients with HIV RNA of less than 400 copies/mL at week 48 was 239 (80{\%}) of 299 in patients receiving tenofovir DF and 253 (84{\%}) of 301 in patients receiving stavudine (95{\%} confidence interval, -10.4{\%} to 1.5{\%}), exceeding the predefined -10{\%} limit for equivalence. However, equivalence was demonstrated in the secondary analyses (HIV RNA",
author = "Gallant, {Joel E.} and Schlomo Staszewski and Pozniak, {Anton L.} and Edwin DeJesus and Suleiman, {Jamal M A H} and Miller, {Michael D.} and Coakley, {Dion F.} and Biao Lu and Toole, {John J.} and Cheng, {Andrew K.}",
year = "2004",
month = "7",
day = "14",
doi = "10.1001/jama.292.2.191",
language = "English (US)",
volume = "292",
pages = "191--201",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients

T2 - A 3-year randomized trial

AU - Gallant, Joel E.

AU - Staszewski, Schlomo

AU - Pozniak, Anton L.

AU - DeJesus, Edwin

AU - Suleiman, Jamal M A H

AU - Miller, Michael D.

AU - Coakley, Dion F.

AU - Lu, Biao

AU - Toole, John J.

AU - Cheng, Andrew K.

PY - 2004/7/14

Y1 - 2004/7/14

N2 - Context: Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. Objective: To evaluate the efficacy and safety of tenofovir DF compared with stavudine in antiretroviral-naive patients. Design, Setting, and Participants: A prospective, randomized, double-blind study conducted at 81 centers in the United States, South America, and Europe from June 9, 2000, to January 30, 2004. A total of 753 patients infected with HIV who were antiretroviral naive were screened and 602 patients entered the study. Intervention Patients were randomized to receive either tenofovir DF (n=299) or stavudine (n=303), with placebo, in combination with lamivudine and efavirenz. Main Outcome Measure: Proportion of patients with HIV RNA levels of less than 400 copies/mL at week 48. Results: In the primary intent-to-treat analysis in which patients with missing data or who added or switched antiretroviral medications before week 48 were considered as failures, the proportion of patients with HIV RNA of less than 400 copies/mL at week 48 was 239 (80%) of 299 in patients receiving tenofovir DF and 253 (84%) of 301 in patients receiving stavudine (95% confidence interval, -10.4% to 1.5%), exceeding the predefined -10% limit for equivalence. However, equivalence was demonstrated in the secondary analyses (HIV RNA

AB - Context: Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. Objective: To evaluate the efficacy and safety of tenofovir DF compared with stavudine in antiretroviral-naive patients. Design, Setting, and Participants: A prospective, randomized, double-blind study conducted at 81 centers in the United States, South America, and Europe from June 9, 2000, to January 30, 2004. A total of 753 patients infected with HIV who were antiretroviral naive were screened and 602 patients entered the study. Intervention Patients were randomized to receive either tenofovir DF (n=299) or stavudine (n=303), with placebo, in combination with lamivudine and efavirenz. Main Outcome Measure: Proportion of patients with HIV RNA levels of less than 400 copies/mL at week 48. Results: In the primary intent-to-treat analysis in which patients with missing data or who added or switched antiretroviral medications before week 48 were considered as failures, the proportion of patients with HIV RNA of less than 400 copies/mL at week 48 was 239 (80%) of 299 in patients receiving tenofovir DF and 253 (84%) of 301 in patients receiving stavudine (95% confidence interval, -10.4% to 1.5%), exceeding the predefined -10% limit for equivalence. However, equivalence was demonstrated in the secondary analyses (HIV RNA

UR - http://www.scopus.com/inward/record.url?scp=3042848853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042848853&partnerID=8YFLogxK

U2 - 10.1001/jama.292.2.191

DO - 10.1001/jama.292.2.191

M3 - Article

C2 - 15249568

AN - SCOPUS:3042848853

VL - 292

SP - 191

EP - 201

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 2

ER -